HYPOTHESIS/COMMENTARY

555 Advances in the Diagnosis and Treatment of Non–Small Cell Lung Cancer
Rathi N. Pillai and Suresh S. Ramalingam

SMALL MOLECULE THERAPEUTICS

557 A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In Vitro and In Vivo
Fardokht Abulwerdi, Chenzhong Liao, Meilan Liu, Asfar S. Azmi, Amro Aboukameel, Ahmed S.A. Mady, Thippeswamy Gulappa, Tomasz Cierpicki, Scott Owens, Tao Zhang, Duxin Sun, Jeanne A. Stuckey, Ramzi M. Mohammad, and Zaneta Nikolovska-Coleska

565 Combined MET Inhibition and Topoisomerase I Inhibition Block Cell Growth of Small Cell Lung Cancer
Cleo E. Rolle, Rajani Kanteti, Mosmi Surati, Suvobroto Nandi, Immanuel Dhanasingh, Soheil Yala, Maria Tretiakova, Qudsia Arif, Todd Hembrough, Tony M. Brand, Deric L. Wheeler, Aliya N. Husain, Everett E. Vokes, Maria Tretiakova, and Ajit Bharti

569 The Fatty Acid Synthase Inhibitor Orlistat Reduces the Growth and Metastasis of Orthotopic Tongue Oral Squamous Cell Carcinomas

576 The AMPK Inhibitor Compound C Is a Potent AMPK-Independent Antiglioma Agent
Xinna Liu, Rishi Raj Chhipa, Ichiro Nakano, and Biplab Dasgupta

581 Disruption of STAT3 by Niclosamide Reverses Radioreistance of Human Lung Cancer
Shuo You, Rui Li, Dongkyoo Park, Maohua Xie, Gabriel L. Sica, Ya Cao, Zhi-Qiang Xiao, and Xingming Deng

585 TPCA-1 Is a Direct Dual Inhibitor of STAT3 and NF-κB and Regresses Mutant EGFR-Associated Human Non–Small Cell Lung Cancers
Jing Nan, Yuping Du, Xing Chen, Qifeng Bai, Yuxin Wang, Xinxin Zhang, Ning Zhu, Jing Zhang, Jianwen Hou, Qin Wang, and Jinbo Yang

596 Disruption of STAT3 by Niclosamide Reverses Radioreistance of Human Lung Cancer
Shuo You, Rui Li, Dongkyoo Park, Maohua Xie, Gabriel L. Sica, Ya Cao, Zhi-Qiang Xiao, and Xingming Deng

606 CBP-Mediated FOXO-1 Acetylation Inhibits Pancreatic Tumor Growth by Targeting SirT
Kartick C. Pramanik, Neel M. Fofaria, Parul Gupta, and Sanjay K. Srivastava

617 Immunoglobulin Fc Domain Fusion to TRAIL Significantly Prolongs Its Plasma Half-Life and Enhances Its Antitumor Activity
Haizhen Wang, Jennifer S. Davis, and Xiangwei Wu

LARGE MOLECULE THERAPEUTICS

622 Dinaciclib (SCH727965) Inhibits the Unfolded Protein Response through a CDK1- and 5-Dependent Mechanism
Tri K. Nguyen and Steven Grant

644 XPO1 (CRM1) Inhibition Represses STAT3 Activation to Drive a Survivin-Dependent Oncogenic Switch in Triple-Negative Breast Cancer
Yan Cheng, Michael P. Holloway, Kevin Nguyen, Dilara McCauley, Yosef Landesman, Michael G. Kauffman, Sharon Shacham, and Rachel A. Altura

CANCER BIOLOGY AND SIGNAL TRANSDUCTION

657 CBP-Mediated FOXO-1 Acetylation Inhibits Pancreatic Tumor Growth by Targeting SirT
Kartick C. Pramanik, Neel M. Fofaria, Parul Gupta, and Sanjay K. Srivastava

March 2014 • Volume 13 • Number 3

Table of Contents
699  Synuclein γ Compromises Spindle Assembly Checkpoint and Renders Resistance to Antimicrotubule Drugs
Suyu Miao, Kejin Wu, Bo Zhang, Ziyi Weng, Mingjie Zhu, Yunshu Lu, Ramadas Krishna, and Yuenian Eric Shi

714  Masitinib Antagonizes ATP-Binding Cassette Subfamily C Member 10–Mediated Paclitaxel Resistance: A Preclinical Study

724  Glioblastoma Cells Containing Mutations in the Cohesin Component STAG2 Are Sensitive to PARP Inhibition
Melanie L. Bailey, Nigel J. O’Neil, Derek M. van Pel, David A. Solomon, Todd Waldman, and Philip Hieter

733  Mutant Ras Elevates Dependence on Serum Lipids and Creates a Synthetic Lethality for Rapamycin
Darin Salloum, Suman Mukhopadhyay, Kaity Tung, Aleksandra Polonetskaya, and David A. Foster

742  microRNAs miR-27a and miR-27b Directly Regulate Liver Dihydropyrimidine Dehydrogenase Expression through Two Conserved Binding Sites
Steven M. Offer, Gabriel L. Butterfield, Calvin R. Jerde, Croix C. Fossum, Natalie J. Wegner, and Robert B. Diasio

752  Cancer-Associated CD43 Glycoforms as Target of Immunotherapy
Franca Maria Tuccillo, Camillo Palmieri, Giuseppe Fiume, Annamaria de Laurentiis, Marco Schiavone, Cristina Falcone, Enrico Iaccino, Ricciarda Galandrini, Cristina Capuano, Angela Santoni, Francesco Paolo D’Armento, Claudio Arra, Antonio Barbieri, Fabrizio Dal Piaz, David Venzon, Patrizia Bonelli, Franco Maria Buonaguro, Iris Scala, Massimo Mallardo, Ileana Quinto, and Giuseppe Scala

763  Sorafenib Inhibits ABCG2 and Overcomes Irinotecan Resistance—Letter
Malcolm A. Smith

764  Sorafenib Inhibits ABCG2 and Overcomes Irinotecan Resistance—Response
Celine Gongora

ABOUT THE COVER
STAT3 and NF-κB signaling pathways are often simultaneously activated in neoplastic cells and play important roles in tumorigenesis and drug sensitivity. TPCA-1, a previously found antagonist of IKKα, blocks STAT3 anchoring to upstream tyrosine kinase and inhibits STAT3 activation induced by cytokines and c-Src. Molecular modeling indicates that TPCA-1 is well docked into SH2 domain of STAT3 and formed hydrogen bond with Glu594. As a direct inhibitor of STAT3 and IKKα, TPCA-1 inhibits growth of non–small cell lung cancer (NSCLC) with EGFR mutation and potentiates the antitumor effect of gefitinib. For details, see article by Nan and colleagues on page 617.